{"id":198432,"date":"2026-07-29T07:52:15","date_gmt":"2026-07-29T13:22:15","guid":{"rendered":"https:\/\/newslink360.space\/?p=198432"},"modified":"2026-07-29T07:52:15","modified_gmt":"2026-07-29T13:22:15","slug":"delgocitinib-cream-improved-atopic-dermatitis","status":"publish","type":"post","link":"https:\/\/newslink360.space\/?p=198432","title":{"rendered":"Delgocitinib Cream Improved Atopic Dermatitis"},"content":{"rendered":"<p><br \/>\n<\/p>\n<div>\n<p>    DELGOCITINIB cream demonstrated dose dependent improvements in adults with mild to severe <a href=\"https:\/\/www.emjreviews.com\/dermatology\/news\/skin-hydration-sensor-for-monitoring-atopic-dermatitis-at-home\/\" target=\"_blank\" rel=\"noopener\">atopic dermatitis<\/a> during an 8 week randomised Phase IIb trial, with greater efficacy observed at higher doses while maintaining a favourable safety profile.<\/p>\n<h2><strong>Dose Response Demonstrated Across Efficacy Endpoints<\/strong><\/h2>\n<p>Researchers evaluated the efficacy and safety of delgocitinib cream in 251 adults with mild to severe atopic dermatitis. Participants were randomly assigned in a 1:1:1:1:1 ratio to receive delgocitinib cream at concentrations of 1 mg\/g, 3 mg\/g, 8 mg\/g, or 20 mg\/g, or a cream vehicle. Treatment was applied twice daily to affected skin areas for 8 weeks.<\/p>\n<p>The primary endpoint was the change in Eczema Area and Severity Index from baseline to week 8. Compared with the cream vehicle, all delgocitinib cream doses produced significantly greater reductions in Eczema Area and Severity Index scores. Mean changes from baseline were: 1 mg\/g: -5.0; 3 mg\/g: -4.9; 8 mg\/g: -5.8; 20 mg\/g: -7.6; compared with -1.9 for the cream vehicle group, with all active treatment groups achieving P&lt;0.05 versus vehicle.<\/p>\n<h2><strong>Higher Doses Produced Greater Clinical Improvement<\/strong><\/h2>\n<p>Exploratory secondary outcomes also reflected a dose dependent treatment response. The proportion of patients achieving Validated Investigator\u2019s Global Assessment for Atopic Dermatitis treatment success increased with higher delgocitinib cream concentrations. Treatment success was achieved by 18.4% of patients receiving 1 mg\/g, 29.2% receiving 3 mg\/g, 30.0% receiving 8 mg\/g, and 48.0% receiving 20 mg\/g, compared with 10.4% in the cream vehicle group.<\/p>\n<p>Similarly, the proportion of patients achieving at least a 75% improvement in Eczema Area and Severity Index from baseline increased across dose groups. Response rates reached 40.8% with 1 mg\/g, 43.8% with 3 mg\/g, 56.0% with 8 mg\/g, and 66.0% with 20 mg\/g, compared with 20.8% for the cream vehicle.<\/p>\n<h2><strong>Safety Profile Supported Continued Development<\/strong><\/h2>\n<p>The incidence of adverse events was comparable between treatment groups. Adverse events occurred in 44.5% of patients receiving delgocitinib cream and 56.0% of those receiving the cream vehicle. The most commonly reported adverse events included upper respiratory tract infection, atopic dermatitis, acne, headache, and application site pruritus. Investigators reported that no new safety concerns were identified during the study period.<\/p>\n<p>Overall, the findings demonstrated that delgocitinib cream provided greater clinical benefit than the cream vehicle across both primary and secondary efficacy outcomes, with improvements increasing alongside dose. The results also indicated that treatment was well tolerated over 8 weeks, supporting the continued clinical evaluation of delgocitinib cream as a topical treatment option for adults with mild to severe atopic dermatitis.<\/p>\n<h2><strong>Reference<\/strong><\/h2>\n<p>Silverberg JI et al. Delgocitinib cream formulation demonstrates a dose-dependent response in adults with mild to severe atopic dermatitis: results from an 8-week randomised Phase IIb trial. Br J Dermatol. 2026; 10.1093\/bjd\/ljag296.<\/p>\n<p><em>Featured image: Aleksej on Adobe Stock<\/em><\/p>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.emjreviews.com\/dermatology\/news\/delgocitinib-cream-showed-dose-dependent-benefits-in-atopic-dermatitis\/\" target=\"_blank\" rel=\"noopener\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DELGOCITINIB cream demonstrated dose dependent improvements in adults with mild to severe atopic dermatitis during an 8 week randomised Phase IIb trial, with greater efficacy observed at higher doses while maintaining a favourable safety profile. Dose Response Demonstrated Across Efficacy Endpoints Researchers evaluated the efficacy and safety of delgocitinib cream in 251 adults with mild &#8230; <a title=\"Delgocitinib Cream Improved Atopic Dermatitis\" class=\"read-more\" href=\"https:\/\/newslink360.space\/?p=198432\" aria-label=\"Read more about Delgocitinib Cream Improved Atopic Dermatitis\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":198433,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[],"class_list":["post-198432","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-national-news"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/newslink360.space\/wp-content\/uploads\/2026\/07\/2pm-derm-7.jpg","jetpack_likes_enabled":true,"jetpack-related-posts":[{"id":194104,"url":"https:\/\/newslink360.space\/?p=194104","url_meta":{"origin":198432,"position":0},"title":"Ferumoxytol Effective Contrast Agent at Low Doses \u2013 EMJ","author":"Ajay Kumar Verma","date":"July 17, 2026","format":false,"excerpt":"FERUMOXYTOL may serve as an effective contrast agent in 3D whole-heart cardiovascular magnetic resonance (CMR) imaging in paediatric and young patients even at a dose of 1 mg\/kg, a new prospective study has found.1 3D Whole-Heart CMR and Ferumoxytol 3D whole-heart imaging is a common CMR technique, widely adopted across\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/9am-radiology-4.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/9am-radiology-4.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/9am-radiology-4.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/9am-radiology-4.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":194905,"url":"https:\/\/newslink360.space\/?p=194905","url_meta":{"origin":198432,"position":1},"title":"Takeda\u2019s QDENGA approved in India, can be given despite pre-exposure to dengue","author":"Ajay Kumar Verma","date":"July 20, 2026","format":false,"excerpt":"Takeda Biopharmaceuticals India has received market authorisation from the Indian drug regulatory authority for QDENGA, its dengue vaccine for prevention of the disease in the 4\u201360 years age group. It is the first dengue vaccine approved in India that can be used in individuals regardless of previous dengue exposure, without\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/IMG_BL30_BUZZ2_2_1_JN8TQQUS.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/IMG_BL30_BUZZ2_2_1_JN8TQQUS.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/IMG_BL30_BUZZ2_2_1_JN8TQQUS.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/IMG_BL30_BUZZ2_2_1_JN8TQQUS.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/IMG_BL30_BUZZ2_2_1_JN8TQQUS.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":196716,"url":"https:\/\/newslink360.space\/?p=196716","url_meta":{"origin":198432,"position":2},"title":"India&#8217;s First Dengue Vaccine Is Here: Who Should Get It And What You Need To Know","author":"Ajay Kumar Verma","date":"July 24, 2026","format":false,"excerpt":"India has approved its first dengue vaccine, marking a significant milestone in the country's efforts to combat one of its most persistent mosquito-borne diseases. The Central Drugs Standard Control Organisation (CDSCO) has granted marketing authorisation for Qdenga, a live, attenuated tetravalent dengue vaccine, making it the first vaccine approved in\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/imresizer-pexels-jorgemendoza80-9344579_20260725093022_ogImage_47.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/imresizer-pexels-jorgemendoza80-9344579_20260725093022_ogImage_47.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/imresizer-pexels-jorgemendoza80-9344579_20260725093022_ogImage_47.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/imresizer-pexels-jorgemendoza80-9344579_20260725093022_ogImage_47.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":197183,"url":"https:\/\/newslink360.space\/?p=197183","url_meta":{"origin":198432,"position":3},"title":"These 3 cool cars will be launched soon! From hybrid to middle class SUV, starting price less than \u20b9 10 lakh","author":"Ajay Kumar Verma","date":"July 25, 2026","format":false,"excerpt":"Upcoming car launches July 2026: Customers are now looking for hybrid, plug-in hybrid (PHEV) and cars with better features beyond just petrol-diesel. In this sequence, 3 big launches are going to happen in July 2026. This includes JSW MG PHEV (Hector Hawk), Maruti Suzuki Brezza Facelift and Toyota Hilux. These\u2026","rel":"","context":"In &quot;Top Stories&quot;","block_context":{"text":"Top Stories","link":"https:\/\/newslink360.space\/?cat=119"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/Upcoming-Cars-July-2026-2026-07-e6d754147508cde2bfe098ecba2a40c4-1200x675.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/Upcoming-Cars-July-2026-2026-07-e6d754147508cde2bfe098ecba2a40c4-1200x675.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/Upcoming-Cars-July-2026-2026-07-e6d754147508cde2bfe098ecba2a40c4-1200x675.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/Upcoming-Cars-July-2026-2026-07-e6d754147508cde2bfe098ecba2a40c4-1200x675.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/Upcoming-Cars-July-2026-2026-07-e6d754147508cde2bfe098ecba2a40c4-1200x675.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":196195,"url":"https:\/\/newslink360.space\/?p=196195","url_meta":{"origin":198432,"position":4},"title":"MG Motor launches premium editions of these two vehicles, only 50 customers will be able to buy them","author":"Ajay Kumar Verma","date":"July 23, 2026","format":false,"excerpt":"MG Select has recently launched Couture Editions of Cyberster and M9, which are limited editions. Production of both models is limited to only 50 units. Pre-reservations have started, while the official announcement of prices will take place on August 3. However, the price details of the standard variant have been\u2026","rel":"","context":"In &quot;Top Stories&quot;","block_context":{"text":"Top Stories","link":"https:\/\/newslink360.space\/?cat=119"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/MG-M9-and-Cyberster-Couture-Editions-2026-07-e0be51748b238b90290739882fd92c6e-1200x675.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/MG-M9-and-Cyberster-Couture-Editions-2026-07-e0be51748b238b90290739882fd92c6e-1200x675.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/MG-M9-and-Cyberster-Couture-Editions-2026-07-e0be51748b238b90290739882fd92c6e-1200x675.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/MG-M9-and-Cyberster-Couture-Editions-2026-07-e0be51748b238b90290739882fd92c6e-1200x675.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/MG-M9-and-Cyberster-Couture-Editions-2026-07-e0be51748b238b90290739882fd92c6e-1200x675.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":194634,"url":"https:\/\/newslink360.space\/?p=194634","url_meta":{"origin":198432,"position":5},"title":"Managing Sleep Deprivation in Clinical Practice","author":"Ajay Kumar Verma","date":"July 19, 2026","format":false,"excerpt":"Physiological Impacts of Sleep Deprivation SUSTAINED sleep deprivation disrupts multiple organ systems, requiring targeted clinical interventions to prevent chronic diseases. Clinical evidence indicates that sleep deprivation triggers acute neuroinflammation by activating microglial pathways and elevating circulating levels of interleukin-6 and tumor necrosis factor-alpha. These inflammatory responses increase blood-brain barrier permeability\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/AdobeStock_2033078174.jpeg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/AdobeStock_2033078174.jpeg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/AdobeStock_2033078174.jpeg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/AdobeStock_2033078174.jpeg?resize=700%2C400&ssl=1 2x"},"classes":[]}],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pgnRh4-PCw","_links":{"self":[{"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/posts\/198432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=198432"}],"version-history":[{"count":0,"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/posts\/198432\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/media\/198433"}],"wp:attachment":[{"href":"https:\/\/newslink360.space\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=198432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=198432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=198432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}